Therefore, adenosine signaling pathway has been targeted by inhibiting either CD73 or A2aR alone, or in combination with ICIs to overcome tumor-mediated immunosuppressive effects in NSCLC [97]. The gene discussed is ADORA2A; the disease is neoplasm.